

ISHL

14

**COLOGNE
GERMANY**



OCTOBER
03-05, 2026

**FINAL
PROGRAM**




GHSG



OCTOBER 03-05, 2026

FINAL PROGRAM

Gürzenich Conference Center • Cologne



The Gürzenich is located in the middle of the city of Cologne. The clipping of the city map gives you an overview about the surroundings of the Gürzenich.

Saturday (03.10.2026)	
08:00	
09:00	08:30-11:00 EHA-LYG / GHSG Joint Session: EHA Clinical Practice Guidelines in Lymphoid Malignancies - From Recommendations to Patient Care (Chairs: I. Aurer, B. v. Tresckow) - Large B-cell lymphomas (S. Leppä) - Mantle cell lymphoma (I. Aurer) - Follicular lymphoma (K. Linton) - HIV-related lymphomas (M. Hentrich) - Peripheral T-cell lymphoma (F. d'Amore) - New Therapeutic Concepts and Horizons in Lymphoma (C. Diefenbach)
10:00	08:30-11:00 Workshop ctDNA in HL (Chairs: S. Allg, S. Borchmann, M. Piroša, C. Steidl) Workshop by ILROG: Individualization of Radiation Therapy for Hodgkin Lymphoma (Chairs: H. T. Eich, J. Yahalom)
11:00	Break
12:00	11:30-13:00 Moving Targets: Rethinking Cellular Therapy Delivery in Aggressive B-Cell Lymphomas by Miltenyi Biomedicine GmbH (Chair: B. v. Tresckow) - R/R DLBCL Treatment Landscape (G. Salles) - Difficult-to-Treat Patients in R/R DLBCL (I. Aurer) - CAR-T Delivery and Treatment Timing: Clinical Challenges and Opportunities (B. v. Tresckow) - Future Directions in Cellular Therapy (A. Sureda)
13:00	Break
14:00	13:15-14:45 Early Stages (Chairs: C. Diefenbach, H. T. Eich) - Personalized RTx: Focus on RTx Techniques and Late Effect Prediction Models (D. Cutter) - Just PD-1 Inhibition? Early Insights from the GHSG INDIE Trial (P. Bröckelmann) - Debate: Should Novel Agents Be Integrated into the Frontline Treatment of Early-Stage Low Risk HL Patients? (G. Collins, C. Diefenbach) - Oral Abstract Presentations
15:00	15:00-16:30 Raising the bar in cHL: Expert perspectives on frontline treatment choice by Bristol Myers Squibb (Chair: P. Borchmann, S. Castellino, A. Herrera) - The current treatment landscape and challenges in cHL (P. Borchmann) - Current and emerging frontline treatment strategies in adult and elderly patients with cHL (A. Herrera) - How we treat advanced stage frontline cHL - N-AVD vs BrECADD (P. Borchmann, A. Herrera, S. Castellino) - Current and emerging frontline and R/R treatment strategies in pediatric patients with cHL (S. Castellino)
16:00	Break
17:00	17:00-18:30 Opening Ceremony and Award Ceremony Keynote Lecture: Changing Treatment Paradigms in B-cell Lymphoma (G. Salles)
18:00	
19:00	18:30-20:00 Poster Session & Welcome Reception

Sunday (04.10.2026)	
08:00-09:15 HL in Children & Adolescents (Chairs: J. Fierlage, C. Mauz-Körholz)	08:00-10:00 Workshop Grassroot Initiative in Classic Hodgkin Lymphoma (Chairs: R. Advani, P. Borchmann, P. Oylro Omond)
- Treatment Evolution in Pediatric Hodgkin Lymphoma: From Research to Real-World Impact (M. Mascarini) - Precision Medicine in Pediatric HL / Harmonized Pediatric HL Protocol in South Africa (J. Geel) - Oral Abstract Presentations	
Break	
09:30-10:30 New concepts for the treatment of B-cell lymphomas by MSD Sharp & Dohme GmbH (Chair: B. v. Tresckow)	
- DLBCL - The current and future role of ADCs in the context of T-cell engaging therapies (B. Chapuy) - cHL - Treatment strategies for PD-1 inhibition in the relapsed / refractory setting (B. v. Tresckow)	
Break	
10:45-12:00 Translating ctDNA into Clinical Routine (Chairs: S. Borchmann, M. Shipp)	
- Circulating Tumor DNA: New Insights from the SWOG S1826 Study (M. Shipp) - Circulating Tumor DNA Analysis for Classification and MRD Assessment - Experience of the German Hodgkin Study Group (S. Borchmann) - Workshop Report (C. Steidl) - Oral Abstract Presentations	
Break	
12:15-13:30 Biology & Pathology (Chairs: W. Klapper, C. Steidl)	
- The Biology of HRS Cells (R. Küppers) - Novel Insights into the Microenvironment of Hodgkin Lymphoma (T. Aoki) - Oral Abstract Presentations	
Break	
13:45-15:15 From Evidence to Experience: How Long-Term and Real-World Data for ADCESTRIS® (brentuximab vedotin) May Inform Frontline Practice in Advanced Hodgkin Lymphoma by Takeda Pharmaceuticals USA, Inc. (Chair: B. v. Tresckow)	
- Enhancing Frontline Management in Advanced HL with BrECADD (O. Balocchi) - Advancing HL Control and Fertility Preservation with BrECADD (E. J. Dann) - Optimizing Care in High-Risk HL with A-AVD (C. Burton)	
Break	
15:30-17:00 Living Beyond Lymphoma (Chairs: M. Büttner, A. Fossá)	
- Evaluating Late Effects of Contemporary Treatments - Competing Risks & Novel Approaches (C. Dietrich) - Uncertainties with Anti-PD-1 & IrAE in the First-Line Setting (P. Bröckelmann) - In Conversation with GHSG Patient Representatives: Building a Bridge Between Cancer Treatment and Everyday Life - Challenges After Lymphoma (K. Behringer, GHSG Patient Representatives) - Oral Abstract Presentations	
17:00-18:30 Advanced Stages (Chairs: P. Armand, G. Collins, M. Hertzberg)	
- Unmet Needs and Future Perspectives with: - BrECADD: Improving Outcomes of HD21 (J. Ferdinandus) - Nivo-AVD: Unanswered Questions from SWOG S1826 (A. Herrera) - Oral Abstract Presentations	

- Scientific Sessions / Main Program
- Closed Workshop, Separate Registration Required
- Scientific Symposia

ISHL 14

COLOGNE GERMANY

OCTOBER 03-05, 2026

FINAL PROGRAM

Gürzenich Conference Center • Cologne

SCIENTIFIC COMMITTEE



Ranjana Advani



Marc André



Stephen Ansell



Philippe Armand



Otavio Balocchi



Christian Baues



Graham Collins



Catherine Diefenbach



Volker Diehl



Hans Theodor Eich



Andrew Evens



Alexander Fosså



Jonathan Friedberg



Herve Ghesquieres



Sylvia Hartmann



Alex Herrera



Mark Hertzberg



Richard Hoppe



Martin Hutchings



Wolfram Klapper



Carsten Kobe



Ralf Küppers



Flora van Leeuwen



Sirpa Leppä



Christine Mauz-Körholz



Alison Moskowitz



Craig H. Moskowitz



Peter Oylro Omondi



Wouter Plattel



John Radford



Andreas Rosenwald



Margaret Shipp



Yuqin Song



Lena Specht



Christian Steldi



Anna Sureda



Bastian von Tresckow



Joachim Yahalom



Josée Zijlstra



Pier Luigi Zinzani



ACKNOWLEDGEMENTS

We wish to express our appreciation and gratitude to our partners.

ACADEMIC SPONSORS



Deutsche
Forschungsgemeinschaft

Financial support was kindly provided by the Deutsche Forschungsgemeinschaft (DFG) within their program "International Scientific Events".

KARL MUSSHOF STIFTUNG

The Karl Musshoff Stiftung kindly supports the Karl Musshoff Prize in the categories "Best Clinical Abstract" and "Best Preclinical Abstract" as well as the "Poster Awards".

B. BRAUN-STIFTUNG

DER GESUNDHEIT NEUE WEGE BEREITEN

Financial support was kindly provided by the B. Braun-Stiftung within their program "Scientific Events".

ACADEMIC PARTNERS



European Board for Accreditation in Hematology



SPONSORS

We thank the following pharmaceutical companies for supporting ISHL:

PLATIN



Takeda Pharmaceuticals USA, Inc. | www.takeda.com



Bristol Myers Squibb | www.bms.com



Miltenyi Biomedicine

Miltenyi Biomedicine GmbH | www.miltenyibiomedicine.com

SILVER



MSD

MSD Sharp & Dohme GmbH
www.msd.de

BRONZE

BeOne Medicines Germany GmbH
www.beonemedicines.de

Natera, Inc.
www.natera.com

EXHIBITION HALL


The scientific exhibition takes place at the Gürzenich Conference Center in the "Isabellensaal" on the first floor.

Opening hours of the Exhibition

Saturday, October 03, 2026 11:00-18:00

Sunday, October 04, 2026 08:00-18:00

Monday, October 05, 2026 08:00-13:00



1. Takeda Pharmaceuticals USA, Inc.
2. MSD Sharp & Dohme GmbH
3. Natera, Inc.
4. Bristol Myers Squibb

Scientific Organisation

Peter Borchmann, MD, Symposium and GHSG Chairman
Justin Ferdinandus, MD, Symposium Co-Chair
Paul J. Bröckelmann, MD, Symposium Co-Chair
Dennis A. Eichenauer, MD, Symposium Co-Chair

German Hodgkin Study Group
Department I for Internal Medicine
University Hospital of Cologne
Kerpener Straße 62, D-50924 Cologne

Phone: +49 (0) 221.478-5933
Fax: +49 (0) 221.478-3778
Email: info@hodgkinsymposium.org
Further Information: www.hodgkinsymposium.org

Conference Management &
Industrial Exhibition Secretariat

Gabriele Hanke
Travel & Congress Activities
Marienburger Str. 8; D-40883 Ratingen
Phone: +49 (0) 2102.669 36
Fax: +49 (0) 2102.9648 29
Email: info@tca-hanke.de

Design: Atelier Henri Winter, www.henri-winter.de
Printed by: Linsen Druckcenter GmbH

Photos by courtesy of: Julia Vogel P. 4/5, 19, 20, 23, 26, 40, 56
Thorsten Kern P. 12, 13 | Köln Kongress P. 14
unsplash.com P. 15, 16/17

WELCOME 11

GENERAL INFORMATION 12-15

SCIENTIFIC PROGRAM

Saturday, 03.10.2026

Scientific Session 1 EHA Clinical Practice Guidelines in Lymphoid Malignancies - From Recommendations to Patient Care 16

Closed Workshop ctDNA in HL 16

Closed Workshop Individualization of Radiation Therapy for Hodgkin Lymphoma 17

Scientific Symposium (Miltenyi Biomedicine GmbH) Moving Targets: Rethinking Cellular Therapy Delivery in Aggressive B-Cell Lymphomas 17

Scientific Session 2 Early Stages 18

Scientific Symposium (Bristol Myers Squibb) Raising the bar in cHL: From frontline treatment to long-term impact 18

Opening Ceremony 19

Poster Session & Welcome Reception 19

Sunday, 04.10.2026

Scientific Session 3 HL in Children & Adolescents 20

Closed Workshop Grassroot Initiative in Classic HL 20

Scientific Symposium (MSD Sharp & Dohme GmbH) New concepts for the treatment of B-cell lymphomas 21

Scientific Session 4 Translating ctDNA into Clinical Routine 21

Scientific Session 5 Biology & Pathology 21

Scientific Symposium (Takeda Pharmaceuticals USA, Inc.) From Evidence to Experience: How Long-Term and Real-World Data for ADCETRIS® (brentuximab vedotin) May Inform Frontline Practice in Advanced Hodgkin Lymphoma 22

Scientific Session 6 Living Beyond Lymphoma 22

Scientific Session 7 Advanced Stages 23

Monday, 05.10.2026

Scientific Session 8 Special Cases & Situations 24

Scientific Session 9 NLPHL 24

Scientific Session 10 Relapsed & Refractory HL 25

Closing Session 25

SPONSORING 26

ORAL AND POSTER PRESENTATIONS

Advanced Stages 27

Biology and Pathology 37

Children and Adolescents 41

Early Stages 43

Living Beyond Lymphoma 45

NLPHL 47

Relapsed and Refractory 48

Resource Constrained Setting 55

SPEAKERS AND CHAIRS 56

WELCOME

Dear Colleagues and Friends,

We warmly welcome you to our 14th International Symposium on Hodgkin Lymphoma (ISHL14), hosted by the German Hodgkin Study Group (GHSG). This Symposium has become the central forum for clinicians and scientists involved in Hodgkin Lymphoma research and therapy, enabling in-depth exchange of the latest results and new ideas. Discussing the relevance of new findings for daily clinical practice in Hodgkin Lymphoma is one of the major goals of this Symposium. It will once more be held at the Gürzenich Conference Center in Cologne, which provides a wonderful communicative environment for discussion and networking.

ISHL14 will cover the most recent results and emerging topics basic research, diagnostics and treatment of Hodgkin Lymphoma. In addition to the presentation of more than 100 abstracts in talks and posters, there will be invited talks, discussions, a workshop and an educational session on new therapeutic approaches in B-cell lymphoma organized jointly with the EHA-LyG. The recipients of the Karl Musshoff Prize in the categories "Best Clinical Abstract" and "Best Preclinical Abstract" will be honoured during the opening ceremony. On top of that, five Poster Awards have been awarded, based on the evaluation of their abstracts by an international committee.

We thank all our contributors and cordially welcome you to ISHL14!



Peter Borchmann
Symposium Chairman



Paul J. Bröckelmann
Symposium Co-Chair



Dennis A. Eichenauer
Symposium Co-Chair



Justin Ferdinandus
Symposium Co-Chair



Peter Borchmann



Paul Bröckelmann



Dennis Eichenauer



Justin Ferdinandus



General Information

Conference Office

Gürzenich Cologne | Martinstraße 29-37 | 50667 Cologne

During the conference, you can contact the Office at

Phone: +49 (0) 173 . 939 07 30

Email: info@tca-hanke.de

Opening Hours of the Conference Office

Saturday, October 03, 2026 07:00-18:30

Sunday, October 04, 2026 07:00-18:30

Monday, October 05, 2026 07:30-13:00

Accommodation

For accommodation support, please contact the conference management:

Phone: +49 (0) 2102 . 669 36

Email: info@tca-hanke.de

Name Badge

Please make sure to always wear your badge at the conference.

If you lose your badge, a replacement fee will be charged.

Catering

During the breaks, complimentary coffee and refreshments will be available.



Cloakroom

The cloakroom is located in the basement.

Conference Language

The conference language is English.

Continuing Medical Education

The 14th International Symposium on Hodgkin Lymphoma is certified by the European Board for Accreditation in Hematology with 16 EBAH credit points.

Please collect your certificates before departure at the registration desk (in the entrance hall of the Gürzenich).

Insurance

The meeting organizers cannot accept liability for personal injuries sustained to Conference participants or for loss or damage of their personal belongings, neither during nor as a result of the meeting.

Internet

There will be free wifi at the Gürzenich Conference Center. Further details and access codes will be provided on site.

Prayer Room

A nondenominational prayer room will be available in the conference center. For further details, please contact the Conference Secretariat.



Registration

Pre-registration will close on *October 1, 2026*. All registrations received on or after *October 2* will be considered as on-site registrations and will be charged the on-site fee.

Full registration will include access to the scientific sessions and exhibition, a copy of the program, the welcome reception on *Saturday (October 03)* and all refreshment breaks. You will also receive a name tag; please wear this name tag at all conference events including the scientific symposia.

No refunds will be given.

Speakers Ready Room

The Speakers Ready Room is located next to the registration desk on the ground floor of the Gürzenich Conference Center. Speakers are requested to hand in their PowerPoint presentations in 16:9 format saved on a stick at least 3 hours before their session or the day before if the session starts early in the morning. We can only accept Microsoft PowerPoint files for upload to the conference system. It is not permitted to use your own laptops or other devices for uploading the files.

Non-Smoking

Please note that there will be a strict non-smoking policy at all conference facilities.



Transportation

The airports closest to Cologne City are Cologne Bonn Airport (CGN; 15km) and Düsseldorf Airport (DUS; 45km).

From Cologne Bonn Airport you can reach Cologne central station by regional rail in about 30 minutes; from Frankfurt Airport to Cologne it takes only an hour by InterCity Express (ICE) and from Düsseldorf Airport about 45 minutes.

Cologne central station is within walking distance (about 10 minutes) from the Gürzenich Conference Center and the Dorint Hotel. You can also take bus no. 132 and get off at "Gürzenichstraße". The other hotels recommended by the Conference Organization can easily be reached by public transport. Cologne has an efficient public transport system, but the recommended hotels, the venue as well as other places of interest are within a comfortable walking distance from each other. For those who are traveling by car, we recommend to use the parking ground "Heumarkt" (about 3 minutes walking distance from the Gürzenich).

Welcome Reception

On Saturday evening, the conference will be opened officially. After the Opening Ceremony, all participants are warmly invited to join the poster session which is accompanied by a Get Together event at the Gürzenich Conference Center. This event is a great opportunity to meet and chat with many colleagues involved in Hodgkin Lymphoma research and treatment. Drinks and snacks will be provided.

PROGRAM

Saturday, 03.10.2026

Scientific Session 1

08:30-11:00

EHA Clinical Practice Guidelines in Lymphoid Malignancies - From Recommendations to Patient Care ROOM: GROSSER SAAL

Igor Aurer (Zagreb, HR), Bastian von Tresckow (Essen, DE)

08:30-08:55 Large B-cell lymphomas	Sirpa Leppä (Helsinki, FI)
08:55-09:20 Mantle cell lymphoma	Igor Aurer (Zagreb, HR)
09:20-09:45 Follicular lymphoma	Kim Linton (Manchester, GB)
09:45-10:10 HIV-related lymphomas	Marcus Hentrich (Munich, DE)
10:10-10:35 Peripheral T-cell Lymphoma	Francesco d'Amore (Aarhus, DK)
10:35-11:00 New Therapeutic Concepts and Horizons in Lymphoma	Catherine Diefenbach (New York, US)

Closed Workshop

08:30-11:00

ctDNA in HL ROOM: MARSILIUSSAAL

Stefan Alig (Essen, DE), Sven Borchmann (Cologne, DE), Maria Piroso (Bellinzona, CH), Christian Steidl (Vancouver, CA)

08:30-09:40 Part I: ctDNA for MRD	Moderator: Maria Piroso (Bellinzona, CH)
10:00-11:00 Part II: ctDNA for Genotyping and Classifying HL	Moderator: Sven Borchmann (Cologne, DE)

Closed Workshop

08:30-11:00

Individualization of Radiation Therapy for Hodgkin Lymphoma ROOM: RATSSTUBE

Hans Theodor Elch (Münster, DE), Joachim Yahalom (New York, US)

Scientific Symposium

11:30-13:00

(Miltényi Biomedicine GmbH)

Moving Targets: Rethinking Cellular Therapy Delivery in Aggressive B-Cell Lymphomas ROOM: GROSSER SAAL

Bastian von Tresckow (Essen, DE)

11:30-11:35 Opening and Framing	Bastian von Tresckow (Essen, DE)
11:35-11:55 R/R DLBCL Treatment Landscape	Gilles Sattes (New York, US)
11:55-12:10 Difficult-to-Treat Patients in R/R DLBCL	Igor Aurer (Zagreb, HR)
12:10-12:25 CAR-T Delivery and Treatment Timing: Clinical Challenges and Opportunities	Bastian von Tresckow (Essen, DE)
12:25-12:40 Future Directions in Cellular Therapy	Anna Sureda (Barcelona, ES)
12:40-13:00 Panel Discussion and Q&A	All faculty

Scientific Session 2

13:15-14:45

Early Stages **ROOM: GROSSER SAAL**

Catherine Diefenbach (New York, US), Hans Theodor Eich (Münster, DE)

13:15-13:35

Personalized RTx: Focus on RTx Techniques and Late Effect Prediction Models David Cutter (Oxford, GB)

13:35-13:55

Just PD-1 Inhibition? Early Insights from the GHSG INDIE Trial Paul Bröckelmann (Cologne, DE)

13:55-14:15

Debate: Should Novel Agents Be Integrated into the Frontline Treatment of Early-Stage Low Risk HL Patients? Graham Collins (Oxford, GB)
Catherine Diefenbach (New York, US)

Q 14:15-14:30 | T082

Radiation-free initial treatment of early-stage favorable classic Hodgkin Lymphoma (RAFTING) trial: three-year follow-up
Gallamini A, Filonenko K, Picardi M, Chauvie S, Filippi A R, Piroso M C, Guerra L, Fallanca F, Bednarek M, Kurlapski M, Domingo-Domènech E, Visentin A, Patti C, García Sanz R, Nunez J, Lopez J, Giza A, Wyszomirski A, Rambaldi A, Rossi D, Sureda A, Zaucha J M

Q 14:30-14:45 | T083

Integrating E-HiPI and Interim PET to Refine Risk Stratification in Early-Stage Classic Hodgkin Lymphoma
Cellini A, De Ferrari M, Assanto G M, Romano A, Santuccio G, Vitale C, Montalbano M C, Angotzi F, Serafin A, Danesin N, Bevilacqua A, D'Antiga M, Leone G, Coscia M, Di Raimondo F, Del Giudice I, Piazza F, Trentin L, Visentin A

Scientific Symposium
(Bristol Myers Squibb)

15:00-16:30

Raising the bar in cHL: From frontline treatment to long-term impact **ROOM: GROSSER SAAL**

Peter Borchmann (Cologne, DE), Sharon Castellino (Atlanta, US), Alex Herrera (Duarte, US)

15:00-15:10

Welcome and Introduction / The current treatment landscape and challenges in cHL Peter Borchmann (Cologne, DE)

15:10-15:30

Current and emerging frontline treatment strategies in adult and elderly patients with cHL Alex Herrera (Duarte, US)

15:30-15:50

How we treat advanced stage frontline cHL - N-AVD vs BRECAAD Peter Borchmann (Cologne, DE), Sharon Castellino (Atlanta, US), Alex Herrera (Duarte, US)

15:50-16:10

Current and emerging frontline and R/R treatment strategies in pediatric patients with cHL Sharon Castellino (Atlanta, US)

16:10-16:25

Panel Q&A session and discussion All faculty

16:25-16:30

Summary and close Peter Borchmann (Cologne, DE)

OPENING CEREMONY

17:00-17:15

Welcome Address Peter Borchmann (Cologne, DE)

17:15-17:45 Award Ceremony

Karl-Musshoff Awards & Abstract Awards

Peter Borchmann, Paul Bröckelmann, Dennis Eichenauer, Justin Ferdinandus

17:45-18:30 Keynote Lecture

Changing Treatment Paradigms in B-cell Lymphoma Gilles Salles (New York, US)

Followed by Welcome Reception during the Poster Session



Poster Session **GÜRZENICH, FOYER**

18:30-20:00

All poster presenters are required to be present at their poster boards from 18:30 to 20:00

Please join the poster presentation and take the chance to discuss the results with your colleagues.

Project Pitch & Collaboration Plaza

Stephen Ansell (Rochester, US), Andrew Evens (New Brunswick, US), Justin Ferdinandus (Cologne, DE), Jonathan Friedberg (Rochester, US), Alex Herrera (Duarte, US), Wouter Plattel (Groningen, NL)

Early Stages

Christian Baues (Bochum, DE), Catherine Diefenbach (New York, US)

HL in Children & Adolescents

Christine Mauz-Körholz (Gießen, DE), Joachim Yahalom (New York, US)

Biology & Pathology

Wolfram Klapper (Kiel, DE), Sirpa Leppä (Helsinki, FI)

Living Beyond Lymphoma

Karolin Behringer (Cologne, DE), John Radford (Manchester, GB)

Advanced Stages

Bastian von Tresckow (Essen, DE), Josée Zijlstra (Amsterdam, NL)

Resource Constrained Settings

Otávio Balocchi (São Paulo, BR), Lena Specht (Copenhagen, DK)

NLPHL

Dennis Eichenauer (Cologne, DE)

Relapsed & Refractory HL

Herve Ghesquieres (Lyon, FR), Pier Luigi Zinzani (Bologna, IT)

Sunday, 04.10.2026

Scientific Session 3

08:00-09:15

HL in Children & Adolescents **ROOM: GROSSER SAAL**

Jamie Flertage (Rochester, US), Christine Mauz-Körholz (Gießen, DE)

08:00-08:20

Treatment Evolution in Pediatric Hodgkin Lymphoma: From Research to Real-World Impact
Maurizio Mascarin (Aviano, IT)

08:20-08:40

Precision Medicine in Pediatric HL / Harmonized Pediatric HL Protocol in South Africa
Jennifer Geel (Johannesburg, ZA)

Q 08:40-08:55 | T071

The Genomic Landscape of Pediatric High-Risk Hodgkin Lymphoma: A Liquid Biopsy Study of COG AHOD1331
Shi S, Marks L J, Srinagesh H K, Osswald L, Allig S K, Adams R, Strohsband M, Kang X, Olsen M N, Liu C L, Renfro L A, Giulino-Roth L, Kelly K M, Bradshaw T J, Diehn M, Cho S Y, Castellino S M, Alizadeh A A

Q 08:55-09:10 | T072

Body-Size Normalisation of Metabolic Tumour Volume in Paediatric Hodgkin Lymphoma: Does MTV/BSA Improve Prognostic Stratification and Reclassify Smaller Children?
Gowdy C, Strahlendorf C, C. Lo A, Mbithi Y, Uribe C, Rahmim A, Yousefirizi F

 Closed Workshop

08:00-10:00

Grassroot Initiative in Classic Hodgkin Lymphoma

ROOM: RATSSTUBE

Ranjana Advani (Stanford, US), Peter Borchmann (Cologne, DE), Peter Oyiro Omondi (Nairobi, KE)



Scientific Symposium

09:30-10:30

(MSD Sharp & Dohme GmbH)

New concepts for the treatment of B-cell lymphomas

ROOM: GROSSER SAAL Bastian von Tresckow (Essen, DE)

09:30-10:00

Diffuse Large B-cell Lymphoma - The current and future role of ADCs in the context of T-cell engaging therapies
Björn Chapuy (Berlin, DE)

10:00-10:30

Classic Hodgkin Lymphoma - Treatment strategies for PD-1 inhibition in the relapsed / refractory setting
Bastian von Tresckow (Essen, DE)

Scientific Session 4

10:45-12:00

Translating ctDNA into Clinical Routine **ROOM: GROSSER SAAL**

Sven Borchmann (Cologne, DE), Margaret Shipp (Boston, US)

10:45-11:05

Circulating Tumor DNA: New Insights from the SWOG S1826 Study
Margaret Shipp (Boston, US)

11:05-11:25

Circulating Tumor DNA Analysis for Classification and MRD Assessment - Experience of the German Hodgkin Study Group
Sven Borchmann (Cologne, DE)

11:25-11:45

Workshop Report
Christian Steidl (Vancouver, CA)

Q T 11:45-12:00 | T048

A Reproducible Mutation- versus Copy-Number-Enriched Genomic Axis Underlies Molecular Subtypes of Classic Hodgkin Lymphoma
Lange C P, Li M Y, Garofalo A, Zamrik T, Reinhardt C, Von Tresckow B, Esfahani M, Alizadeh A A, Steidl C, Aoki T, Allig S K

Scientific Session 5

12:15-13:30

Biology & Pathology **ROOM: GROSSER SAAL**

Wolfram Klapper (Kiel, DE), Christian Steidl (Vancouver, CA)

12:15-12:35

The Biology of HRS Cells
Ralf Küppers (Essen, DE)

12:35-12:55

Novel Insights into the Microenvironment of Hodgkin Lymphoma
Tomohiro Aoki (Toronto, CA)

Q 12:55-13:10 | T046

Functional characterization of STAT6 mutations as oncogenic drivers in classical Hodgkin lymphoma (cHL)
Tasselli L, B. Coan R L, Pensato V, Le Dily F, Müller-Coan B G, Pettrossi V, Blanco E, Cupola A, Pasqualucci L, Di Croce L, Tlaccl E

Q 13:10-13:25 | T047

Artificial intelligence predicts EBV status and reveals prognostic morphology phenotypes in advanced-stage classic Hodgkin lymphoma
Tharmaseelan H, Winderl D, Gretser S, Richter J, Ferdinandus J, Borchmann P, Altenbuchinger M, Klapper W

Scientific Symposium
(Takeda Pharmaceuticals USA, Inc.) 13:45-15:15

From Evidence to Experience: How Long-Term and Real-World Data for ADCETRIS® (brentuximab vedotin) May Inform Frontline Practice in Advanced Hodgkin Lymphoma

ROOM: GROSSER SAAL Bastian von Tresckow (Essen, DE)

13:45-13:50 Welcome and Introductions	Bastian von Tresckow (Essen, DE)
13:50-14:10 Enhancing Frontline Management in Advanced HL with BrECADD	Otávio Baiocchi (São Paulo, BR)
14:10-14:30 Advancing HL Control and Fertility Preservation with BrECADD	Eldad J. Dann (Haifa, IL)
14:30-14:50 Optimizing Care in High-Risk HL with A+AVD	Cathy Burton (Leeds, GB)
14:50-15:10 Engage with the Experts (Q&A)	All faculty
15:10-15:15 Meeting close	Bastian von Tresckow (Essen, DE)

Scientific Session 6 15:30-17:00

Living Beyond Lymphoma ROOM: GROSSER SAAL

Maximilian Büttner (Ditzingen, DE), Alexander Fosså (Oslo, NO)

15:30-15:50 Evaluating Late Effects of Contemporary Treatments - Competing Risks & Novel Approaches	Caroline Dietrich (Solna, SE)
15:50-16:10 Uncertainties with Anti-PD-1 & irAE in the First-Line Setting	Paul Bröckelmann (Cologne, DE)
16:10-16:30 In Conversation with GHSG Patient Representatives: Building a Bridge Between Cancer Treatment and Everyday Life - Challenges After Lymphoma	Karolin Behringer (Cologne, DE) GHSG Patient Representatives

Q 16:30-16:45 | T092
Patients with a history of Hodgkin lymphoma have lower quality of life than matched comparators regardless of time elapsed since diagnosis
Godtfredsen S J, Baech J, Andersen M P, Yonis H, Jensen P, Kamper P, Christensen J H, Sørensen R B, Hutchings M, Torp-Pedersen C, Sogaard P, Boggild H, Kragholm K H, El-Galaly T C

Q 16:45-17:00 | T093
The MyHodgkin MyHealth App: patient-derived data for tracking Hodgkin Lymphoma survivorship
Wong Doo N, Josiah A A, Klemm G, Meli L, Ganesh A, Tohidi-Esfahani I, Falconer J, Low R, Lawrence P, Di Ciaccio P R, Propper E, Weekes N, Harris E, Chapman N, Winton S, Trotman J

Scientific Session 7 17:00-18:30

Advanced Stages ROOM: GROSSER SAAL

Philippe Armand (Boston, US), Graham Collins (Oxford, GB), Mark Hertzberg (Westmead, AU)

Unmet Needs and Future Perspectives with:

17:00-17:20 Justin Ferdinandus (Cologne, DE)
BrECADD: Improving Outcomes of HD21

17:20-17:40 Alex Herrera (Duarte, US)
Nivo-AVD: Unanswered Questions from SWOG S1826

Q 17:40-17:55 | T001
CHOP/miniCHOP And Tisletlizumab in Elderly patients with classical Hodgkin Lymphoma (cHL). A report of the phase II CATER-HL trial (HD12) from the Australasian Lymphoma and Leukaemia Group (ALLG)
Cochrane T, Lee S T, Gasiorowski R, Gangatharan S A, Roncolato F, Renwick W E, Simpson J, Johnston A, Hahn U, Wong P, Lasica M, Solterbeck A, Traficante R, Mapp S, Devitt B, Pandya D, Carlson J, Gerber T, Hertzberg M, Hawkes E, Keane C

Q 17:55-18:10 | T002
Simplified Geriatric Assessment (sGA) in Older Patients With Classical Hodgkin Lymphoma (cHL): The Prospective ELDHL Project of the Fondazione Italiana Linfomi (FIL)
Ziloli V R, Merli F, Tucci A, Luminari S, Colloca G, Muzi C, Puccini B, Pagani C, Vitale C, Rossi F G, Meli E, Guidetti A, Maifredi S, Marino D, Fabbri A, Maschio N, Gotti M, Bernardelli A, Mancuso S, Mele A, Gini G, Del Giudice I, Bigliardi S, Scarpa E, Botto B, Margiotta-Casaluci G, Soccodato A M, Tani M, Liso A, Kurtapski M, Flenghi L, Merli A, Sica A, Ricci F, Perutelli F, Battistini R, Ferreri A J M, Laszlo D, Gaudio F, Zanni M, Cencini E, Tabanelli V, Guerra L, Agostinelli C, Marcheselli L, Mammi C, Spina M, Arcari A

Q 18:10-18:25 | T003
Durable Remissions and Late Immune-Related Toxicities After Frontline Pembrolizumab + AVD in Classic Hodgkin Lymphoma
Lynch R, Kuczmarski T, Ujjani C, Poh C, Warren E, Smith S, Shadman M, Till B, Raghunathan V, Tseng Y, Du H, Rasmussen H, Voutsinas J, Gopal A



Monday, 05.10.2026

Scientific Session 8 08:00-09:15

Special Cases & Situations ROOM: GROSSER SAAL

Paul Bröckelmann (Cologne, DE), Josée Zijlstra (Amsterdam, NL)

08:00-08:20 HL in Pregnancy	Anne Sophie Robertz (Cologne, DE)
08:20-08:40 Critical Organ Failure at Presentation	Hishan Tharmaseelan (Cologne, DE)
08:40-09:00 Anti-PD-1 Tx In Pre-Existing Autoimmune Disease	Yvonne Jauw (Amsterdam, NL)
09:00-09:15 Workshop Report "Grassroot Initiative in Classic Hodgkin Lymphoma"	Ranjana Advani (Stanford, US) Peter Oyiro Omondi (Nairobi, KE)

Scientific Session 9 09:30-10:30

NLPHL ROOM: GROSSER SAAL

Richard Hoppe (Stanford, US), Wolfram Klapper (Kiel, DE)

09:30-09:45 Clinical Implications of Growth Patterns	Dennis Eichenauer (Cologne, DE)
09:45-10:05 Treatment Strategies	Jamie Flerlage (Rochester, US)

- Q 10:05-10:18 | T101
Single-Nuclei and Spatial Transcriptomic Analysis of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dong H, Rambow-Makhzami S, Vorneweg M, Wichmann F, Jurmeister P, Bühnen I, Rosenwald A, Klapper W, Von Tresckow B, Reinhardt C, Klauschen F, Bernd H, Hansmann M, Eichenauer D, Hartmann S, Rambow F
- Q 10:18-10:30 | T102
Malignant LP cells build a stroma-poor, avascular niche that concentrates IDO1+ macrophages and excludes regulatory T cells in NLPHL and THRLBCL
Kalashnikov I, Leivonen S, Kalander K, Autio M, Dunkel J, Färkkilä A, Leppä S

Scientific Session 10 10:45-12:15

Relapsed & Refractory HL ROOM: GROSSER SAAL

Craig H. Moskowitz (Miami, US), Anna Sureda (Barcelona, ES)

10:45-11:05 2L Treatment of HL in the Era of Novel Agents	Alison Moskowitz (New York, US)
11:05-11:20 Revisiting the Role of Stem Cell Transplantation in rrHL	Bastian von Tresckow (Essen, DE)
11:20-11:35 Unmet Needs and Novel Treatment Approaches in >3L	Martin Hutchings (Copenhagen, DK)

- Q 11:35-11:48 | T106
Phase 1 PRIMAVERA Study of the PRMT5 Inhibitor AZD3470 in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma
Zinzani P L, Morschhauser F, Ribrag V, Phillips E H, Ghesquieres H, Lee H J, Borchmann P, Bröckelmann P J, Kim T M, Lewis K, Svoboda J, Rodriguez Izquierdo A, Kim W S, Sureda A, Collins G P, Beyfuss K, Dos Santos C, Olsson R F, Derenzini E
- Q 11:48-12:01 | T107
Treatment patterns and survival outcomes of patients relapsing after frontline Nivolumab-AVD in advanced stage classical Hodgkin lymphoma (cHL)
Shah H, Bock A, Hao P, Qiao X, Stuver R, Thiruvengadam S, Borogovac A, Merryman R, Araujo N, Falade A, Houshyar S, Reef D, Smilnak G, Sekaran K, Luttwak E, Sano D, Major A, Mynam R, Baek G, Sharp J, Vaughn J, Ramakrishnan Geethakumari P, Desai S, Allen J, Baron K, Chang T, Ganesan N, Patel V, Palmeri M, Abhyankar A, Gerber D, Iqbal M, Chergn H, Niu A, Rhodes J, Svoboda J, Diefenbach C, Voorhees T, Di M, Pophali P, Karimi Y, Karmali R, Shanmugasundaram K, Grover N, Durani U, Micallef J N, Friedberg J W, Feldman T, Mei M, Torka P, Armand P, Moskowitz A, Herrera A, Epperla N
- Q 12:01-12:15 | T108
Primary Analysis of the GHSG Pembro-CORE Trial: PET-Adapted PD-1-Based Salvage Therapy Omitting High-Dose Chemotherapy in First-Relapsed Hodgkin Lymphoma
Tharmaseelan H, Bühnen I, Kaul H, Gillessen S, Kobe C, Schrenk K G, Ernst P, Topp M S, Schnetzke U, Freund N, Sasse S, Klapper W, Fuchs M, Borchmann S, Bröckelmann P J, Borchmann P, Von Tresckow B

Closing Session ROOM: GROSSER SAAL 12:15-13:00

12:15-12:45 Best of ISHL14	Ranjana Advani (Stanford, US)
12:45 Farewell	Peter Borchmann (Cologne, DE)



We would very much like to thank all of our partners for their generous sponsoring.

Name of Sponsor	Total Sponsoring Amount	Sponsoring Benefit
BeOne Medicines Germany GmbH	€ 10.000,00	Educational
Bristol Myers Squibb	€ 65.000,00	Symposia and Booth
Miltenyi Biomedicine GmbH	€ 60.000,00	Symposia
MSD Sharp & Dohme GmbH	€ 43.000,00	Symposia and Booth
Natera, Inc.	€ 5.000,00	Booth
Takeda Pharmaceuticals USA, Inc.	€ 75.000,00	Symposia and Booth

ABSTRACTS

ORAL AND POSTER PRESENTATIONS

Posters will be presented during the Poster Session and Welcome Reception on Saturday, October 03 (18:30-20:00).
Poster presenters are kindly asked to be present at their boards throughout the session to discuss their results with colleagues.

Advanced Stages

Talks

Q T001

CHOP/miniCHOP And Tislelizumab in Elderly patients with classical Hodgkin Lymphoma (cHL). A report of the phase II CATER-HL trial (HD12) from the Australasian Lymphoma and Leukaemia Group (ALLG)
Cochrane T, Lee S T, Gasiorowski R, Gangatharan S A, Roncolato F, Renwick W E, Simpson J, Johnston A, Hahn U, Wong P, Lasica M, Solterbeck A, Traficante R, Mapp S, Devitt B, Pandya D, Carlson J, Gerber T, Hertzberg M, Hawkes E, Keane C

Q T002

Simplified Geriatric Assessment (sGA) in Older Patients With Classical Hodgkin Lymphoma (cHL): The Prospective ELDHL Project of the Fondazione Italiana Linfomi (FIL)
Zilloli V R, Merli F, Tucci A, Luminari S, Colloca G, Muzi C, Puccini B, Pagani C, Vitale C, Rossi F G, Meli E, Guidetti A, Maifredi S, Marino D, Fabbri A, Maschio N, Gotti M, Bernardelli A, Mancuso S, Mele A, Gini G, Del Giudice I, Bigliardi S, Scarpa E, Botto B, Margiotta-Casaluci G, Soccodato A M, Tani M, Liso A, Kurlapski M, Flenghi L, Merli A, Sica A, Ricci F, Perutelli F, Battistini R, Ferreri A J M, Laszlo D, Gaudio F, Zanni M, Cencini E, Tabanelli V, Guerra L, Agostinelli C, Marcheselli L, Mammi C, Spina M, Arcari A

Q T003

Durable Remissions and Late Immune-Related Toxicities After Frontline Pembrolizumab + AVD in Classic Hodgkin Lymphoma
Lynch R, Kuczmarski T, Ujjani C, Poh C, Warren E, Smith S, Shadman M, Till B, Raghunathan V, Tseng Y, Du H, Rasmussen H, Voutsinas J, Gopal A

P004

Low-dose nivolumab combined with AVD chemotherapy (Nivo40-AVD) for advanced classic Hodgkin lymphoma: interim results
Akhmedov M, Zeynalova P, Vernyuk M, Semochkin S, Khairullina L, Cherkashina I, Chervontseva A, Lunin V, Fedenko A, Kaprin A

P005

Real-World Tolerability and Efficacy of BrECADD in Advanced-Stage Hodgkin Lymphoma: A Multicenter Brazilian Experience
Peruzini G, Garcia M, De Barros R, De Moura T, Samico R, Zing N, Brito R, Bovolenta V, Schimdt J, Braga A, Fisher T, Silveira T

P006

BrECADD in Three Days: Condensing an Intensive First-Line Regimen in Classic Hodgkin Lymphoma
Jaworek C P, Supprian M, Bröckelmann P J, Tharmaseelan H, Ferdinandus J, Eichenauer D, Robertz A S, Jablonski J, Combüchen V, Staak J, Töpelt K, Heger J, Rischewski J F, Stemler J, Klapper W, Von Tresckow B

P007

Six Cycles of Pembrolizumab (PEM) Induction Followed by Abbreviated AVD: A Phase II Trial of Front-Line PET-adapted Therapy in Early Unfavorable and Advanced-Stage Classic Hodgkin Lymphoma (cHL)
Melody M, Savas H, Schroers-Martin J, Karmali R, Ma Y, Mangan C, Zehra W, Avery R, Carson K, Faruqi F, Shaikh H, Chen R, Cheng R, Gordon L, Advani R, Winter J

P008

Real-world experience with first-line Nivolumab-AVD in advanced-stage Classical Hodgkin Lymphoma
Hernández Mohedo F, Curras Sanchez L, Jiménez Blanco L, Martínez Conejo A I, Escudero Soler M T, Rubio De La Rubia M L, Ramos Font C, Puerta Puerta J M

P009

PRECISE-HL Trial: Personalized Reduction of Chemotherapy Intensity through ctDNA Evaluation in Advanced Hodgkin Lymphoma
Lynch R, Russler-Germain D, Schroers-Martin J, Moskowitz A, Merryman R, Borogovac A, Du H, Rasmussen H, Advani R, Alizadeh A A, Armand P, Bartlett N, Herrera A, Rutherford S, Kurtz D, Gooley T, Voutsinas J, Gopal A

P010

Frontline Escalation to BrECADD in Advanced Hodgkin Lymphoma: Multicenter Real-World Experience
Porges T, Levi T, Buqai T, Dann E J

P011

Interim analysis of the A-AVD PET2 adapted in patients with stage IV classical Hodgkin lymphoma. The AVATAR program
Visentin A, Cellini A, Angotzi F, De Ferrari M, D'Antiga M, Giordano A, Danesin N, Pizzi M, Grassetto G, Vianello F, Piazza F, Gallamini A, Trentin L

P012

KEYNOTE-204 final analysis: An open-label, phase 3 study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory (R/R) classic Hodgkin lymphoma (cHL)
Kuruvilla J, Santoro A, Walewski J, Gasiorowski R, Johnson N, Melnichenko V, Buccheri V, Giacon P, Fogliatto L M, Goncalves I, Perini G, Alekseev S, Goldschmidt N, Kriachok I, Strzala J, Dickinson M, Lojko-Dankowska A, McDonald A, Ozcan M, Ghori R, Park D, Yusuf R, Zinzani P L

P013

Subcutaneous Pembrolizumab (Pembro) in Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or Primary Mediastinal Large B-cell Lymphoma (PMBCL): Additional Follow-Up From a Phase 2 Study
Phillips E H, Barragán Ibáñez G, Paszkiewicz-Kozik E, Jurczak W, Chandia Cabas M, Portiño S, Aladag Karakulak E, Glebel S, Sureda A, Kim T M, González-García B, Gutiérrez N, Hidalgo S, Ardeshta K, Rodríguez Izquierdo A, Von Tresckow B, Song G, Flynn J, Ryland K, Yusuf R, Ozcan M

P014

Changes in Patient Reported Outcomes and Treatment Tolerance with a Structured Diet and Exercise Plan

Stanchina M, Lopez-Pentecost M, Natori A, Alderuccio J, Trabolsi A, Alencar A, Panzner E, Freylersythe G, Crane T, Moskowitz C

P015

High efficacy and acceptable toxicity of BrECADD regimen in advanced-stage classical Hodgkin lymphoma

Mocikova H, Gaherova L, Brizova B, Steinerova K, Michalka J, Kral Z, Lukasova M, Prochazka V, Sykorova A, Stepankova P, Hradská K, Duras J, Vackova B, Koren J, Kozak T

P016

FENIX Score: A Novel PET-Derived Signature Predicting Neurotoxicity in Advanced Hodgkin Lymphoma Treated with A+AVD

Cristante M, Fallanca F, Calimeri T, Ferreri A J M, Marino F

P017

Frontline Use of Nivolumab with Doxorubicin, Vinblastine, and Dacarbazine in Advanced-Stage Classical Hodgkin Lymphoma: A Real-World Analysis

Gahérová L, Kozák T, Michalka J, Cermanová M, Král Z, Vacková B, Kořen J, Sýkorová A, Hradská K, Steinerová K, Lukášová M, Móciková H

P018

Interim PET remains clinically informative during frontline nivolumab-based therapy in advanced-stage classical Hodgkin lymphoma

Kravtsova A, Koroleva D, Shchetsova O, Bagova M, Magomedova A, Margolin O, Gitelzon E, Subbotin A, Zvonkov E, Mangasarova Y

P019

Real-World Treatment Options and Outcomes of Hodgkin Lymphoma In Hungary

Dr Miltényi Z, Borics F, Tóthfalusi D, Fülöp-Dobó B, Pinczés L I, Illés A

P020

Efficacy and Safety of the combination of Programmed Death -1 inhibitors (PD-1i) with chemotherapy for the treatment of classical Hodgkin's Lymphoma (cHL). A single center experience

Papanastassi K, Triantafyllou P, Giatra C, Loutsidi N - E, Tolia A, Patrinos A, Tszilioni E, Kotsifas L, Giannikou E, Vasillelou M, Massaoutis C, Rondogianni P, Baltadakis I, Bouzani M

P021

Vanishing Bile Duct Syndrome as a Paraneoplastic Manifestation of Hodgkin Lymphoma

Kodrul E, Filatova L, Volchenkov S, Elkhova S, Lomazov A, Kramynin L, Kolgotina A, Zverkova A, Ishmatova I, Kolupaev N, Eliseeva A, Zyuzgin I

P022

Association of Patlak-derived dynamic FDG PET parameters with Deauville response categories and kinetic heterogeneity of residual PET-positive findings in classical Hodgkin lymphoma: a prospective single-center pilot study

Horňák G, Hanáčková V, Lukášová M, Ptáček J, Procházka V, Kamínek M

P023

Real-World Effectiveness and Safety of the BrECADD Regimen in Advanced Hodgkin Lymphoma. A Multicenter Observational Study of the Polish Lymphoma Research Group.

Rybka J, Wróbel T, Czyż A, Bućdyś K, Grygoruk-Wiśniowska I, Długosz-Danecka M, Sawicki M, Malesa K, Dybko J, Paszkiewicz-Kozik E, Kurlapski M, Kruczkowska-Tarantowicz K, Kołkowska-Leśniak A, Lech-Marańda E, Migryt-Rogala E, Gil J, Kopacz A, Kopińska A, Janus A, Giza A, Zaucha J M

P024

Anthracycline-containing regimens confer better survival in risk-matched, advanced stage older patients with classic Hodgkin lymphoma; comorbidity, not age, predicts cardiac toxicity

Barrett A, Kirkwood A, McKay P, Osborne W, Shah N, Jamil F, De Silva R, Fawcett J, Crosbie N, Hardman J, Idris S, Lee C, Truelove E, Hmaid A, Iyengar S, McDonald L, Miall F, Lalng H, Talbot G, Hasan S, Dai S, Santarsieri A, Wann S L, Marzolini M, Paterson J, Lawless S, Waddell D, Trickey R, Davies T, Radhakrishnan V, Sridhar S, Phillips E H, Dallatorre C, Toth P, McCarthy P, Chernucha E, Pandit M, Percy L, Easton J, McCulloch R, Wolf J, Wells M, Quinn D, Kuhn L, Subklewe C, Cook L, Atkins O, Gallop-Evans E, Williams K, Burton C, Collins G P

P025

Validation of the Hodgkin Lymphoma Simplified Frailty Score for Patients Receiving Modern Regimens

Sobol K, Luttwak E, Chang T, Ganeson N, Torka P, Moskowitz A

P026

Fitness-adapted, pembrolizumab-based therapy for untreated classical Hodgkin Lymphoma (cHL) patients (Pts) 60 years of age and above: a multicenter prospective study

Portell C, Horton B, Brighton D, Svoboda J, Orellana-Noia V, Evens A M

P027

Cost-effectiveness analysis of N-AVD vs BrECADD in advanced-stage classic Hodgkin lymphoma

Kim J L, Kelkar A H, Parsons S, Moskowitz A, Patel K, Nedved A, Khurana A, Villasboas Bisneto J C, Paludo J, Abeykoon J P, Tiger Y K, Hampel P J, Wang Y, Lin Y, Bennani N N, Porrata L F, Thanarajasingam G, Thompson C A, Johnston P B, Micaleff I N, Habermann T M, Witzig T E, Armand P, Ansell S M, Durani U

P028

First-line BrECADD in routine clinical practice: excellent treatment deliverability and early efficacy in advanced-stage classical Hodgkin lymphoma

Hude Dragičević I, Babić Čukman K, Bašić-Kinda S, Dreta B, Dujmović D, Batinić J, Dobrenić M, Galunić-Bilić L, Aurer I

P029

Ten-year follow-up of ECHELON-1: overall survival and long-term safety with Brentuximab vedotin plus AVD versus ABVD in patients with previously untreated advanced classic Hodgkin lymphoma

Ansell S M, Straus D J, Connors J M, Jurczak W, Kim W S, Gallamini A, Picardi M, Feldman T, Savage K J, Ramchandren R, Zinzani P L, Abramson J S, Collins G P, Friedberg J W, Grigg A, Turgut M, Hutchings M, Advani R, Scheliga A, Evens A M, Bush R, Sedarati F, Jie F, Fanale M, Radford J

P030

Outcome and Prognostic Value of PET-2 in Stage IV Classical Hodgkin Lymphoma Treated with Frontline Brentuximab Vedotin Plus AVD: A Real-World Multinational GELTAMO-GATLA Study

Trucco J I, Peña M, Marti M T, Korin L, Figueroa Mora M R, Martinez C, Antelo Perez G, Zerga M, Navarro M B, Mahuad C, Carpio C, Alonso Prieto C M, Fiad L, Cannata-Ortiz M J, Rocca M, Kellenher N, Rosenhain M, Sanchez Gonzalez B, Salvano L, Villalon Blanco L, Romano J, Musso V, Comai A, Warley F, Santorum C, Negri Aranguren F, Orlova M, Cerutti A, Drouet V, Sardu L, Viviani T, Valerga Couste J, Domingo-Doménech E, Sureda A, Pavlovsky A

P031

Multistate Modeling of Disease Trajectories for Advanced-Stage Hodgkin Lymphoma Patients Receiving PET Response-Adapted Therapy

Cui Z J, Tighiouart H, Counsell N, Rossetti S, Upshaw J, Kirkwood A, Li H, Advani R, Casanovas O, Cerhan J, Federico M, Gallamini A, Ghesquieres H, Hawkes E, Hodgson D, Hutchings M, Johnson P, Link B, Mou E, Radford J, Savage K J, Stephens D, Zinzani P L, Maurer M, Rossi C, Evens A M, Parsons S, Rodday A M

P032

ABVD versus a risk-stratified and a response adapted strategy- addressing the dilemma in Advanced Hodgkin Lymphoma: A Phase III Randomized Study

Jain H, Padmanabhan A, Shetty A, Nayak L, Bagal B, Thorat J, Elpe T, More S, Khatavkar N, Ganesan P, Vasudevan S, Goda J, Gujral S, Shet T, Kode J, Agrawal A, Rangarajan V, Shah S, Sharma N, Sridhar E, Laskar S, Sengar M

P033

Evaluating the outcomes of elderly Hodgkin Lymphoma patients: a focus on sequential Brentuximab-AVD

Cellini A, Angotzi F, De Ferrari M, Danesin N, D'Antiga M, Bevilacqua A, Giordano A, Pizzi M, Crimi F, Grassetto G, Vianello F, Piazza F, Trentin L, Visentin A

P034

Netupitant/palonosetron for prevention of chemotherapy-induced nausea and vomiting in Hodgkin lymphoma treated with ABVD or BV-AVD: a single-centre observational study

Cellini A, Angotzi F, Zatta I, De Ferrari M, Serafin A, Bevilacqua A, Danesin N, Leone G, D'Antiga M, Giordano A, Piazza F, Tempurin F, Trentin L, Visentin A

P035

In-Field Recurrence Patterns Following Consolidation Radiotherapy after BrECADD in Advanced-Stage Hodgkin Lymphoma: A Secondary Analysis of the Randomized Phase 3 GHSG HD21 Trial

Rosenbrock J, Supprian M, Oertel M, Ferdinandus J, Tharmaseelan H, Jaworek C P, Ferdinandus S, Weindler J, Bröckelmann P J, Dapper H, Kobe C, Fuchs M, Fokas E, Borchmann P, Eich H T, Baues C

P036

Interim PET-Adapted De-escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Study - Updated Follow-up

Lee H J, Ravizzini G, Ramos J, Retamales J, Chauhan A, Fayad L, Nair R, Westin J, Henderson J, Flowers C, Wang M, Malpica L

P037

PET-Adapted EACODD-14 Regimen in Early Unfavorable and Advanced Stages of Classical Hodgkin Lymphoma: Efficacy and Survival in the Multicenter HL-Russia-1 Study

Shorokhov N, Demina E, Tumyan G, Spirko V, Pavluchenko E, Kaplanov K, Bobrova A, Baryakh E, Ivanova D, Mikhailova N, Borzenkova E, Pospelova T, Voytko M, Smirnova O, Kankumasheva E, Siraeva E, Kanin V, Saidullaeva A, Adolf A, Matveeva I, Mochkin N, Melnichenko V, Sarzhevskiy V

P038

Frontline nivolumab-AVD in older patients with advanced classical Hodgkin lymphoma: real-world experience from a single Italian centre

Lazic T, Luminari S, Bavleri A, Gambara S, Nizzoli M E, Arletti L, Ferrari A, Ilariucci F, Merli F

P039

Has Frontline Brentuximab Vedotin Plus AVD Altered the Historical Adverse Prognostic Impact of Stage IV Disease in Classical Hodgkin Lymphoma? A Dual-Center Real-World Experience

Berliner M, Lazic T, Sciarra R, Mazzacane A, Pedrali S, Rampi N, Rusconi C, Arcaini L, Luminari S, Gotti M

P040

Hyperbilirubinemia in Classical Hodgkin Lymphoma: Impact of Severity on Hepatic Recovery and Clinical Outcomes

Patel Y, Lakshmi K, Korula A, Mathews V

P041

INTERIM AND END-OF-TREATMENT (EOT) PET/CT ASSESSMENT AFTER NIVOLUMAB, DOXORUBICIN, VINBLASTINE, AND DACARBAZINE (N-AVD) IN ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA (CHL): A SINGLE-CENTER EXPERIENCE

Alexia P, Liaskas A, Kopsaftopoulou A, Dimitrakoudi M, Konstantinou E, Belia M, Arapaki M, Fioretzaki R, Kolotsiou A, Machairas A, Poultzaki G, Chatzidimitriou C, Asimakopoulos J, Georgopoulou A, Zerzi C, Tsaftaridis P, Panitsas F, Benekou A, Petsa P, Plata H, Bitsani A, Dimou M, Siakantaris M, Angelopoulou M, Vassilakopoulos T

P042

Association of quantitative FDG-PET parameters and serum TARC with outcome in advanced classic Hodgkin lymphoma: A biomarker analysis of the EORTC-1537-COBRA trial

Teesink S, Visser L, Musekera L, Sureda A, Carvalho S, Vranovsky A, Loft A, Arens A, Tonino S, Sents W, Mallien C, Aleman B, Noordzij W, Fortpied C, Hutchings M, Diepstra A, Plattel W

P043

LUNG FUNCTION ASSESSMENT BY DIFFUSING CAPACITY OF THE LUNGS FOR CARBON MONOXIDE (DLCO) MEASUREMENT IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA RECEIVING FIRST-LINE TREATMENT WITH NIVOLUMAB-AVD

Liaskas A, Piperidou A, Poultasaki G, Dimitrakoudi M, Kopsaftopoulou A, Floretzaki R, Machairas A, Belia M, Arapaki M, Konstantinou E, Assimakopoulos G, Tsaftaridis P, Panitsas F, Bitsani A, Dimou M, Siakantaris M, Angelopoulou M, Vassilakopoulos T

P044

HIV-associated Hodgkin lymphoma: real-world treatment outcomes and infectious complications - a multicentre study by the Polish Lymphoma Research Group

Giza A, Zapala M, Drozd-Sokolowska J, Witkowska M, Zaucha J M, Sobczyk-Kruszelnicka M, Szlauer-Stefanska A, Kopinska A, Zawartko M, Witek- Jedra M, Wisniewski K, Wdowiak K, Grzyb J, Parfieniuk-Kowerda A, Leonczuk N, Wandalowicz A, Joks M, Rybka J, Strzala J, Szeremet A, Szymczak A, Czarnecki M, Głuchowska M, Dybko J, Zimowska-Curylo D, Lech-Maranda E, Sacha T, Parczewski M, Bociaga-Jasik M

P045

Frontline BV-AVD in Classical Hodgkin Lymphoma: A Multicenter Real-World Comparison with the ABVD Regimen

Keklik Karadag F, Yuksel M, Yilmaz U, Ulukoylu Menguc M, Çetin D, Gunes A, Bulan B, Tan T, Yigitkaya S, Afacan Ozturk H B, Elgün E, Gören D, Hasanzade U, Bulbul Dilmen H, Iltar U, Erdogan Yon M E, Cengiz Seval G, Salim O, Yücel O K, Kircali E, Serenli Yeğen Z, Erol H A, Uysal A, Deveci B, Kayıkçı O, Narlı Özdemir Z, Oğuz Kozan E, Baysal M, Eroğlu Küçükçıldır A H, Demirci Z, Yavasoglu I, Aytaç P, Özmen İbis D, Özbalak M, Özkalemkas F, Gunes A K, Sevindik O G, Özet G, Gulbas Z, Akay O M, Ar M C, Eskazan A E, Birtas Atesoglu E, Ferhanoglu B, Saydam G, Özcan M, Mehtap O

Biology & Pathology**Talks****Q T046**

Functional characterization of STAT6 mutations as oncogenic drivers in classical Hodgkin lymphoma (cHL)

Tasselli L, B. Coan R L, Pensato V, Le Dily F, Müller-Coan B G, Pettirossi V, Blanco E, Cupola A, Pasqualucci L, Di Croce L, Tiacci E

Q T047

Artificial Intelligence predicts EBV status and reveals prognostic morphology phenotypes in advanced-stage classic Hodgkin lymphoma

Tharmaseelan H, Winderl D, Gretser S, Richter J, Ferdinandus J, Borchmann P, Altenbuchinger M, Klapper W

Q T048

A Reproducible Mutation- versus Copy-Number-Enriched Genomic Axis Underlies Molecular Subtypes of Classic Hodgkin Lymphoma

Lange C P, Li M Y, Garofalo A, Zamrik T, Reinhardt C, Von Tresckow B, Esfahani M, Alizadeh A A, Steidl C, Aoki T, Alig S K

Posters**P049**

Detection of traces of EBNA2 in the Microenvironment of Pediatric Classical Hodgkin Lymphoma Reveals Its Immunomodulatory Role

Mangiaterra T, Lindl K, Jimenez O, De Matteo E, Chabay P

P050

VARIANT HISTOLOGY IN PEDIATRIC NLPBL: ADVERSE FEATURES MITIGATED BY R-CHOP, INCLUDING FEASIBLE EARLY-STAGE DE-ESCALATION

Ali N, Moussa E, Khorshed E, Zaghloul M, Elnashar A, Abdalla A

P051

Genetic tumor cell heterogeneity and genomic instability in classic Hodgkin lymphoma

Klotz S, Budeus B, Schramm F, Beeck L K, Weniger M A, Bröckelmann P J, Küppers R

P052

Emerging role of SAMHD1 in anti-tumor immune responses and sensitivity to chemotherapy in classical Hodgkin lymphoma

Trogrlic D, Psaroudaki E, Mermelekas G, Yang Y, Bougka E, Nordentoft C, Herold N, Lundqvist A, Drakos E, Rassidakis G

P053

Development of CD30 CAR T-cells co-expressing an anti-PDL1.CD28 chimeric switch receptor for the treatment of r/r cHL

Katsin M, Dormeshkin D, Migas A, Klych H, Meleshko A, Natalya K, Doroshenko T

P054

Elucidation of transcriptomic tumor cell heterogeneity and micro-environment in classic Hodgkin lymphoma

Schramm F, Klotz S, Budeus B, Beeck L K, Weniger M A, Bröckelmann P J, Küppers R

P055

RHOA Mutation Analysis Identifies Potential nTFHL Among Cases With Classic Hodgkin Lymphoma Morphology

Yamada R, Nishimura M F, Nishikori A, Nishimura Y, Suzuki R, Sato Y

P056

Predictive significance of immunohistochemistry in patients with Hodgkin's lymphoma on the size of the tumor mass and IPS score

Sretenovic S, Jovanovic D, Djurdjevic P, Mirkovic N

P057

Baseline PET Radiomics for Risk Stratification in Classic Hodgkin Lymphoma

Heider A, Subramanian A, Sandfort V, Park N, Xing L, Hoppe R, Alizadeh A A, Schroers-Martin J, Advani R, Binkley M

P058

The TIGIT/CD155 Immune Checkpoint Axis in Classical Hodgkin Lymphoma: Clinical and Prognostic Implications

Annibali O, Marafioti T, Tomarchio V, Ghosh A, Antonelli L, Alsharabati M, Iachino S, Hunter H, Santoro G, Padmasri S, Bianchi A, Spreafico S, Crescenzi A, Rigacci L

P059

Secondary hemophagocytic lymphohistiocytosis after autologous HSCT: clinical vigilance in the absence of classical criteria

Kodrul E, Volchenkov S, Filatova L, Elkhova S, Zyuzgin I

P060

Clinical relevance of serum TARC levels below 1000 pg/ml in Hodgkin lymphoma: a hidden biomarker?

Borics F, Dobó B, Gulyás A, Tóthfalusi D, Pinczés L I, Illés A, Miltényi Z

P061

Familial Presentation of Classical Hodgkin Lymphoma in First-Degree Relatives

Dobó B, Tóthfalusi D, Borics F, Pinczés L I, Illés A, Miltényi Z

P062

Correlating 18FDG-PET/CT- and CT-derived Biomarkers to Neutrophil Extracellular Traps in Classical Hodgkin Lymphoma

Pettersson E, Korenyushkin A, Chauhan A, Tarai S, Collin J, Amini R, Molin D, Olsson A, Ahlström H, Kullberg J, Enblad G

P063

Genetic Clustering Reveals Biologic Similarities Across subgroups of Hodgkin Lymphoma, Primary Mediastinal Large B-Cell Lymphoma and Large B-Cell Lymphoma patients

Rischewski J F, Briest F, Mattlener J, Noerenberg D, Schleifenbaum J K, Schneider J, Heidenreich S, Heger J, Damm F, Borchmann S

P064

Time-of-Day Immunotherapy Administration and Outcomes in Classic Hodgkin Lymphoma

Schroers-Martin J, Yu A, Yeung A, Silin C, Powell M, Binkley M, Hoppe R, Advani R

P065

Redefining Hodgkin lymphoma pathogenesis: the central and indispensable role of CD 4 T cells

Diepstra A, Lei Y, Teesink S, Plattel W, Visser L

**P066**

The Role of CD59 in Mediating T Cell Rosette Formation in Classic Hodgkin Lymphoma

Lei Y, Alcala R M, Seltz A, Visser L, Diepstra A

P067

Fragmentomics analysis to enhance ctDNA based risk stratification in Hodgkin Lymphoma

Schneider J, Mattlener J, Heidenreich S, Schleifenbaum J K, Freihammer M, Schütte D, Borchmann P, Gödel P, Balke-Want H, Reinhardt C, Von Tresckow B, Schwarz R, Heger J, Borchmann S

P068

Plasma Proteomic Profiling of Classical Hodgkin Lymphoma

Risebro R, Collin J, Ulfstedt J M, Pettersson E, Hellström M, Glimelius I, Berglund M, Enblad G, Freyhult E, Molin D

P069

Analysis of circulating tumor DNA shows Epstein-Barr virus associated differences of mutagenic processes in classical Hodgkin lymphoma.

Kupcova K, Gaheerova L, Velasova A, Maco M, Hamova I, Nehasil P, Zemankova P, Stepankova P, Kredatusova A, Markova J, Vackova B, Koren J, Sykorova A, Prochazka V, Kozak T, Mocikova H, Havranek O

P070

Kinetics of PD-1 Blockade on Circulating CD8+ve T Cells After Exposure to low-dose Nivolumab

Korula A, Datari P, Arunachalam A, Mathews V

HL in Children & Adolescents

Talks

Q T071

The Genomic Landscape of Pediatric High-Risk Hodgkin Lymphoma: A Liquid Biopsy Study of COG AHOD1331

Shi S, Marks L J, Srinagesh H K, Osswald L, Alig S K, Adams R, Strohsand M, Kang X, Olsen M N, Liu C L, Renfro L A, Giulino-Roth L, Kelly K M, Bradshaw T J, Diehn M, Cho S Y, Castellino S M, Alizadeh A A

Q T072

Body-Size Normalisation of Metabolic Tumour Volume in Paediatric Hodgkin Lymphoma: Does MTV/BSA Improve Prognostic Stratification and Reclassify Smaller Children?

Gowdy C, Strahlendorf C, C. Lo A, Mbithi Y, Uribe C, Rahmim A, Yousefirizi F

Posters

P073

Outcomes of Pediatric Hodgkin Lymphoma Patients treated with ABVD Regimen. A retrospective Cohort Study

Abdel Rahman H, Moussa E, Sedky M, Ali N, El Sayed W, Farouk M, Talaat S, Rashad H, Khorshed E, Saad Zaghloul M, Roshdy E, El Wakeel M

P074

Outcomes of Second-Line EuroNet Salvage Regimens in Pediatric Patients with Relapsed and Primary Refractory Hodgkin Lymphoma

Moussa E, Badawy s, Hamouda A, Attia A, Talaat s, Abdelrahman H, Ali N, Sedqy M, Ezz El Din N, El Sayed W, Farouk M, Fakhry M, Shoukry E, Taher y, El Nashaar A, Saad Zaghloul M, Naguib E, Roushdy E, El Wakeel M, Abdelaziz R, El Haddad A

P075

Response Adapted Therapy of Pediatric Classic Hodgkin Lymphoma According to Modified EURO-NET Protocol-Single Center Experience
Abdel Rahman H, Ali N, Fakhry M, Farouk M, Shoukry E, Mahmoud N, Attia A, El Sayed W, Sedky M, Taher Y, Abdel Aziz R, Hamoda A, Talaat S, Khorshed E, Saad Zaghloul M, Roushdy E, El Wakeel M, Badawy S, Kamal M, Moussa E, El Haddad A

P076

ATAXIA TELANGIECTASIA ASSOCIATED PEDIATRIC HODGKIN LYMPHOMA: HIGH RESPONSE RATES BUT SUBSTANTIAL NON RELAPSE MORTALITY
Ali N, Abdelrahman H, Moussa E, Radwan N, Khorshed E, Badawy S, Elsayed W

P077

Real-World Outcomes of IGEV Salvage Therapy in Relapsed or Refractory Pediatric Hodgkin Lymphoma: Challenges from a Resource-Limited Setting
Elsayed W, Salama M, Abdelrahman H, Moussa E, Medany Y, Saad Zaghloul M, El Wakeel M, Khorshed E, Roshdy E, Ali N

P078

Baseline and Delta PET/CT Radiomics for Prognostic Stratification in Paediatric Hodgkin Lymphoma
Gowdy C, Strahlendorf C, C. Lo A, Mbithi Y, Uribe C, Rahmim A, Yousefirizi F

P079

Survival benefit of brentuximab vedotin in classical Hodgkin lymphoma: a multicenter real-world study
Zhang W, Wang Y, Hu S, Jiang M, Wen S, Liu W

P080

Feasibility of tumor microenvironment analysis in pediatric and adolescent classical Hodgkin lymphoma by automated cyclic immunofluorescence staining
Albracht M, Yalcin F, Richter J, Reinke S, Braun M, Rohde M, Claviez A, Maecker-Kolhoff B, Burkhardt B, Borkhardt A, Feuchtinger T, Tröger A, Ebinger M, Escherich G, Schneider D, Klusmann J, Thorwarth A, Körholz D, Mauz-Körholz C, Klapper W

P081

Allogeneic stem cell transplantation for multiply recurrent EBV-driven classic Hodgkin lymphoma arising in the setting of suspected activated PI3-kinase delta syndrome (APDS) associated with a novel variant: a case report spanning 13 years
Debettencourt J, Hale R, Schienda J, Keating A, Harris M, Lehmann L, Feraco A

Early Stages

Talks

Q T082

Radiation-free initial treatment of early-stage favorable classic Hodgkin Lymphoma (RAFTING) trial: three-year follow-up
Gallamini A, Filonenko K, Picardi M, Chauvie S, Filippi A R, Piroso M C, Guerra L, Fallanca F, Bednarek M, Kurlapski M, Domingo-Domènech E, Visentin A, Patti C, García Sanz R, Nunez J, Lopez J, Giza A, Wyszomirski A, Rambaldi A, Rossi D, Sureda A, Zaucha J M

Q T083

Integrating E-HIPI and Interim PET to Refine Risk Stratification in Early-Stage Classic Hodgkin Lymphoma
Cellini A, De Ferrari M, Assanto G M, Romano A, Santuccio G, Vitale C, Montalbano M C, Angotzi F, Serafin A, Danesin N, Bevilacqua A, D'Antiga M, Leone G, Coscia M, Di Raimondo F, Del Giudice I, Piazza F, Trentin L, Visentin A

Posters

P084

Role of consolidative radiotherapy in preventing relapses and subsequently salvage ASCT in early-stage classic Hodgkin Lymphoma
Dada R, Apostolidis J, Belal Ibrahim R, Ahmed Salem A, Ibrahim Mahmoud M, Asif Iqbal H, Boubakra T, Ghatasheh H, Halahleh K

P085

Definition of a risk collective for high cardiac radiation doses - A post-hoc analysis of the HD17 study by the German Hodgkin Study Group reference radiation oncology panel

Oertel M, Kittel C, Steike D R, Fuchs M, Baues C, Vordermark D, Engenhart-Cabilic R, Herfarth K, Schmidberger H, Lukas P, Borchmann P, Eich H T

P086

TRIAL IN PROGRESS: PRIORITY (PET guided dose Reduction for Involved site Radiotherapy In early sStage unfavourable Hodgkin lymphoma: a randomized, phase III, non-inferiority study)

Ricardi U, Matrone F, Botto B, Levis M, Ciammella P, Evangelista A, Iamundo De Cumis I, Chauvie S, Ricci F, Stefani P M, Rigacci L

P087

AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children & Adults with Newly Diagnosed Stage I & II Classic Hodgkin Lymphoma

Seelisch J, Hu B, Renfro L A, Duvall A, Wu Y, Cho S Y, Hoppe B S, Milgrom S, Mailhot Vega R, Lo A C, Hodgson D, Guilino Roth L, Grover N, Steward Lacasce A, Kahn J M, Parsons S, Hinds P S, Allen P B, Evens A M, Schoder H, Castellino S M, Kelly K M

P088

Individualizing Consolidative Radiotherapy in Intermediate-Stage Hodgkin Lymphoma: A PET-Residual Re-Planning Analysis of Patients from the GHSG HD17 Trial

Steike D R, Oertel M, Hölken P, Lohmann S, Schulze N, Rosenbrock J, Fuchs M, Vordermark D, Engenhart-Cabilic R, Herfarth K, Schmidberger H, Lukas P, Baues C, Dabaja B, Borchmann P, Eich H T

P089

Real-world implementation of a modified PET-adapted HD17 approach in early-stage Hodgkin lymphoma: a single-centre audit

Papadaki A S, Morrice R, Ardeshta K, Cwynarski K, Gohil S, Kayani I, Sivabalasingham S, Lambert J, Mcnamara C, Mohamedbhai S, Northend M, Al-Sader H, Batool A, Ringshausen I, Rismani A, Virchis A, Townsend W, Marzolini M

P090

Omission of Radiotherapy is Associated with Inferior Progression-Free Survival in Bulky and Interim-PET-Positive Early-Stage Hodgkin Lymphoma: A Propensity-Matched Multicenter Real-World Analysis

Dreyfuss A, Dave N, Moskowitz A, Yahalom J, Alfaro M, Birrer N, Hu B, Koch R, Frosch Z, Colton M, Ho C, Amoozgar B, Feldman T, Saxena A, Rhodes J, Dunton A, Shah N, Mantione A, Hubbeling H, Lariviere M, Plastaras J, Desai B, Imber B, Muenzen R, Barta S, Carter J, Chong E, Cook M, Landsburg D, Nasta S, Schuster S, Thomas C, Tomasulo E, Svoboda J

P091

Characteristic of patients with a positive end of treatment PET or experiencing early relapse despite interim PET negativity: analysis from the EORTC-LYSA-FIL H10 trial.

Rigacci L, Plattel W, André M, Marcheselli L, Aleman B, Ricardi U, Christinelli C, Gotti M, Re A, Hutchings M, Edeline V, Bellei M, Merli F, Stamatoulas A, Tonino S, Ribrag V, Botto B, Federico M

Living Beyond Lymphoma

Talks

Q T092

Patients with a history of Hodgkin lymphoma have lower quality of life than matched comparators regardless of time elapsed since diagnosis

Godtfredsen S J, Baeck J, Andersen M P, Yonis H, Jensen P, Kamper P, Christensen J H, Sprensen R B, Hutchings M, Torp-Pedersen C, Sogaard P, Boggild H, Kragholm K H, El-Galaly T C

Q T093

The MyHodgkin MyHealth App: patient-derived data for tracking Hodgkin Lymphoma survivorship

Wong Doo N, Josiah A A, Klemm G, Meli L, Ganesh A, Tohidi-Esfahani I, Falconer J, Low R, Lawrence P, Di Ciaccio P R, Propper E, Weekes N, Harris E, Chapman N, Winton S, Trotman J

P094

Evidence of Statistical Cure for Hodgkin Lymphoma With Contemporary Treatment: A Non-mixture Cure Model Analysis

Chen J, Huang Y, Jiang M, Yao Z, Wang Y, Zhang W, Zhu J, Song Y, Wen S, Shi Y, Liu W

P095

Chemotherapy-induced peripheral neuropathy and quality of life among Hodgkin lymphoma survivors treated at an older age - A national cross-sectional study

Galleberg R B, Lia K, Fagerli U M, Bø I B, Smeland K B, Rostoft S, Hjermstad M J, Johansen J, Bhargava S, Kiserud C E, Sjørlund K, Mols F, Fluge Ø, Fosså A

P096

Frailty as a predictor of survival in older patients with classical Hodgkin lymphoma: A retrospective, multicenter study from the RELINF Spanish Lymphoma Registry of the GELTAMO Spanish Lymphoma Group

Domingo-Doménech E, Martínez Muñoz C, Rodríguez Nuñez R M, Sanchez Gonzalez B, Moreno M, Alonso Castronuño D, Cannata-Ortiz M J, Gomez Prieto P, Benito L, Torrado T, Buch J, Arevalo C, Caballero J C, Domínguez N, Santiago R, Gonzalez-Gascon I, Moya Arnao M, Carpio C, Gutierrez-Meca Maestre M D, Lopez Gomez L A, Gainza E, Figueroa Mora M R, Fernandez-Caldas P, Villafuerte Gutierrez P, Romero S, Navarro B, Zeberio Etxetxipia I, Parda E, Gutierrez A, Donato E, Nuñez J, Cobo T, García Sanz R, Gomez Roncero M I, Barrenetxea C, De La Nuez H, Dorado Lopez A, Trelles R, Sanchez Val L I, Martín-Consuegra S, Bengochea M L, Alonso Prieto C M, Ramila E, Peñarrubia M J, Ortiz A, Mahillo I, Cordoba R

P097

The Psychological Impact of Lung Cancer Screening in Hodgkin Lymphoma Survivors

Brusven M, Seale T, Linton K, Broadbent R

P098

Impact of Exercise Interventions during chemotherapy in functional capacity and patient-reported outcomes in patients with Hodgkin lymphoma

Martinez De Rituerto Zeberio M, Mendibil Esquisabel B, Goicoechea Pellejero H, Tous Espelosin M, Olazabal Elizaguirre I, Madinabeitia J, Iriondo Alzola J, Maldonado Martín S, Zeberio Etxetxipia I

P099

Factors Associated with Survivorship Care Engagement Among Pediatric Hodgkin Lymphoma Survivors

Shliakhtsitsava K, Rao A, Gargan L, Cochran C, Watt T, Rettig E, Bowers D, Eary R, Hughes A

P100

Long-term follow up after Lymphoma treatment in young adults

Rugelj U, Zadavec Zatelet L, Štrbac D, Toplak M

NLPHL**Talks****Q T101**

Single-Nuclei and Spatial Transcriptomic Analysis of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

Dong H, Rambow-Makhzami S, Vorneweg M, Wichmann F, Jurmeister P, Bühnen I, Rosenwald A, Klapper W, Von Tresckow B, Reinhardt C, Klauschen F, Bernd H, Hansmann M, Eichenauer D, Hartmann S, Rambow F

Q T102

Malignant LP cells build a stroma-poor, avascular niche that concentrates ID01+ macrophages and excludes regulatory T cells in NLPHL and THRLBCL

Kalashnikov I, Leivonen S, Kalander K, Autio M, Dunkel J, Färkkilä A, Leppä S

P103

Data Scarcity in Rare Lymphoma: Synthetic Patient Generation and Survival Analysis in NLPHL

Santangelo G, Fresi E, Ferretti V, Berliner M, Pedrali S, Mazzacane A, Dagliati A, Gotti M

P104

Pembrolizumab In Relapsed/Refractory Nodular Lymphocyte-Pre-dominant Hodgkin Lymphoma: A Case Report

Rodríguez Santos P, Pierdomenico F, Sousa P, Esteves G, Cabçadas J, Gomes Da Silva M

P105

Management and Outcomes in Pediatric Nodular Lymphocyte-Pre-dominant Hodgkin Lymphoma: Evidence from a Brazilian Multicenter Cohort

Morais A, Costa J, Costa A R, Palese M, Binkley M, Flerlage J

Relapsed & Refractory HL

Talks

Q T106

Phase 1 PRIMAVERA Study of the PRMT5 Inhibitor AZD3470 in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma

Zinzani P L, Morschhauser F, Ribrag V, Phillips E H, Ghesquieres H, Lee H J, Borchmann P, Bröckelmann P J, Kim T M, Lewis K, Svoboda J, Rodríguez Izquierdo A, Kim W S, Sureda A, Collins G P, Beyfuss K, Dos Santos C, Olsson R F, Derenzini E

Q T107

Treatment patterns and survival outcomes of patients relapsing after frontline Nivolumab-AVD in advanced stage classical Hodgkin lymphoma (cHL)

Shah H, Bock A, Hao P, Qiao X, Stuver R, Thiruvengadam S, Borogovac A, Merryman R, Araujo N, Falade A, Houshyar S, Reef D, Smilnak G, Sekaran K, Luttwak E, Sano D, Major A, Mynam R, Baek G, Sharp J, Vaughn J, Ramakrishnan Geethakumari P, Desai S, Allen J, Baron K, Chang T, Ganesan N, Patel V, Palmeri M, Abhyankar A, Gerber D, Iqbal M, Cherng H, Niu A, Rhodes J, Svoboda J, Diefenbach C, Voorhees T, Di M, Pophali P, Karimi Y, Karmali R, Shanmugasundaram K, Grover N, Durani U, Micallef I N, Friedberg J W, Feldman T, Mei M, Torka P, Armand P, Moskowitz A, Herrera A, Epperla N

Q T108

Primary Analysis of the GHSG Pembro-CORE Trial: PET-Adapted PD-1-Based Salvage Therapy Omitting High-Dose Chemotherapy in First-Relapsed Hodgkin Lymphoma

Tharmaseelan H, Bühnen I, Kaul H, Gillessen S, Kobe C, Schrenk K G, Ernst P, Topp M S, Schnetzke U, Freund N, Sasse S, Klapper W, Fuchs M, Borchmann S, Bröckelmann P J, Borchmann P, Von Tresckow B

Posters

P109

Immune Checkpoint Inhibitor Combined with Radiotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma: A Transplant-Free Retrospective Study

Liu Y, Wang J, Wu Y, Liu X, Song Y, Qi S, Li Y

P110

How to manage BrECADD failure? Early Outcomes of Second-Line Treatment in classic Hodgkin Lymphoma

Jaworek C P, Jablonski J, Sgonina L M, Rudat A, Fichtel P, Melchardt T, Ghandili S, Rank A, Hänel M, Meissner J, Halbsguth T, Tharmaseelan H, Ferdinandus J, Bröckelmann P J, Borchmann P, Von Tresckow B

P111

KEYFORM-008: Randomized Phase 2 Study of Coformulated Faveze-
limab/Pembrolizumab Versus Chemotherapy in Participants With
Relapsed or Refractory Classic Hodgkin Lymphoma

*Bröckelmann P J, Lavie D, Perini G, Ozcan M, Johnson N, Kim W S,
Mahud C, Gutiérrez N, Maral S, Borel C, Kim T M, Goncalves I,
Jagadeesh D, Karimi Y, Wagner-Johnston N, Timmerman J, Lynch R,
Collins G P, Sidi Y, Pillai P, Yusuf R, Herrera A*

P112

Preliminary Results of Nivolumab and Axatilimab in Patients with
Relapsed/Refractory Classical Hodgkin Lymphoma refractory to
anti-PD-1 therapy

*Shah H, Modi D, Boucher K, Marvin J, Zak J, Pomicter A, Baron K,
Ermann D, Moskowitz A, Ramchandren R, Stephens D, Hu B*

P113

Eight-year outcomes after nivolumab discontinuation in patients
with relapsed/refractory classic Hodgkin lymphoma

*Fedorova L, Lepik K, Kotselyabina P, Kondakova E, Chekalov A,
Borzenkova E, Mikhailova N, Kulagin A*

P114

Low-Dose Nivolumab Combined with Salvage Chemotherapy in
Relapsed/Refractory Classic Hodgkin Lymphoma: Outcomes from a
Tertiary Care Centre in North India

*Singh C, Jandial A, Jain A, Khadwal A, Basher R, Bal A, Prakash G,
Malhotra P*

P115

Outcomes in Double-Exposed Classical Hodgkin Lymphoma: The Im-
pact of Treatment Sequence and Salvage Strategies After Brentux-
imab Vedotin and Checkpoint Inhibitor Failure

*Marinoni M, Aoki T, Bhella S, Gong I, Kridel R, Kukreti V, Prica A,
Vijenthira A, Yang C, Wells W, Rodin D, Hodgson D, Crump M,
Kuruvilla J*

P116

PD-1 Inhibitor maintenance after Auto-HCT in r/r Classical Hodgkin
lymphoma with prior PD-1 exposure: interim phase II results

*Kotselyabina P, Balaeva A, Fedorova L, Bogatyrev V, Shorokhov N,
Mochkin N, Akhmedov M, Vernyuk M, Cherkashina I, Karabekov A,
Sarzhevskiy V, Demina E, Keimakin V, Mikhailova N, Kulagin A*

P117

Association of prior PD-1 inhibitor exposure with pre-engraftment
syndrome after ASCT in relapsed/refractory Hodgkin lymphoma

*Tóthfalusi D, Csatlós G M, Dobó B, Borics F, Pinczés L I, Illés A,
Miltényi Z*

P118

Autologous hematopoietic cell transplantation remains relevant de-
spite PD-1 inhibitor-based second-line therapy in classic Hodgkin
lymphoma: interim results from the Prolgo-HL study

*Fedorova L, Kotselyabina P, Lepik K, Chekalov A, Markelov V,
Shpirko V, Semenova A, Tumyan G, Volchenkov S, Piletskaya A,
Zyuzgin I, Konoplya N, Mikhailova N, Kulagin A*

P119

Efficacy of Ultra-Low-Dose Nivolumab in Combination with Gem-
citabine and Cisplatin as Remission-Induction Therapy in Primary
Progressive and Relapsed Hodgkin Lymphoma: A Randomized Phase
II study with two ultra-low-dose schedules

*Prakash M, Joshi N, Karumathil S, Selvarajan S, Lionel S, Kulkarni U,
Abraham A, George B, Mathews V, Korula A*

P120

From Clinical Trials to Clinical Practice: A Decade of Experience with
Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma

*Sykorova A, Koren J, Maule E, Gaherova L, Lukasova M, Duras J,
Steinerova K, Stepankova P, Vackova B, Michalka J, Markova J,
Prochazka V, Brizova B, Trnny M, Kral Z, Blahovcova P, Mocikova H*

P121

Brentuximab vedotin as bridging and maintenance therapy in hematopoietic cell transplant in a national access program for relapsed or refractory classical Hodgkin lymphoma patients

Fernandez-Vargas O, Rivas-Vera S, Agreda-Vásquez G, Mucius I, Balandrán-Ruiz M, Gómez-Almaguer D, Cruz-Rico J, Colunga-Pedraza P, Balderas-Delgado C, Best C, Barragán G, Cardiel M, Alcivar M L, Galvez-Acosta S, Sosa R E, Pérez Karen D, Ron-Magaña A L

P122

BCL-2 Inhibition Combined with Other Therapeutic Agents Demonstrates Synergistic Efficacy in Hodgkin Lymphoma Cells

Niu A, Brosnick N, Mavis C, Cortese M, Hernandez-Ilizaliturri F

P123

Real-World Data on the Single-Agent Pembrolizumab Therapy in Relapsed / Refractory Classic Hodgkin Lymphoma Patients in the Czech Republic.

Michalka J, Móciková H, Hradská K, Sýkorová A, Procházka V, Folber F, Maule E, Gahérová L, d'uraš J, Obadalová B, Štěpánková P, Lukášová M, Král Z

P124

Activity of Nivolumab with Decitabine Cedazurine (DEC-C) in Relapsed/Refractory Hodgkin Lymphoma (cHL): Results from an ETCTN Phase 1 Study

Kline J, Tusciano J, Goyal G, Mei M, Davis A, Shapiro G, Diefenbach C

P125

Three cycles of nivolumab (N) before BGD chemotherapy improves the remission rate before autologous hematopoietic cell transplantation (aHCT) in relapsed/refractory Hodgkin Lymphoma: N-BUR-GUND trial of the Polish Lymphoma Research Group (PLRG).

Taszner M, Paszkiewicz-Kozik E, Wyszomirski A, Rybka J, Chromik K, Kołkowska-Leśniak A, Subocz E, Targoński Ł, Ceklarz P, Witkowska M, Swoboda R, Domańska-Czyż K, Giza A, Kobylecka M, Voltin C, Romejko-Jarosińska J, Ostrowska B, Świerkowska M, Druzd-Sitek A, Kurlapski M, Bednarek M, Małkowski B, Romanowicz G, Hałka J, Wróbel T, Giebel S, Helbig G, Lech-Marańda E, Zaucha J M

P126

REAL WORLD EFFICACY AND SAFETY COMPARISON OF SALVAGE REGIMENS COMBINING BRENTUXIMAB VEDOTIN AND CHEMOTHERAPY IN SECOND-LINE HODGKIN LYMPHOMA: A LYSA MULTICENTER RETROSPECTIVE STUDY.

Wencel J, Pages A, Chevillon F, Noël R, Laemmel L, Vignac M, Corvilain E, Sfeir P, Kohn M, Fouquet G, Lohez M, Delapierre B, Basile G, Laboure G, Cherait A, Soussain C, Grenier A, Braun T, Ricard L, Andre A, Deau B, Cheminant M, Galtier J, Dutari P, Renaud L

P127

(Bv)DHAP + G-CSF as an effective peripheral stem cell mobilization regimen in adult patients with relapsed/refractory Hodgkin lymphoma

Shapetska M, Iskrau I, Valevskaya M, Gerasimovich O, Smolnikova V

P128

EHA-4448 REAL-WORLD OUTCOMES OF PEMBROLIZUMAB PLUS GVD AS SALVAGE THERAPY AND BRIDGE TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: A MULTICENTER GATLA STUDY

Pavlovsky A, Warley F, Salvano L, Orlova M, Guanchiale L, Korin L, Mahuad C, Trucco J I, Cerutti A, Negri Aranguren F, Antelo Perez G, Wannesson B, Romano J, Sardu L, Musso V, Macchiavello E L, Scebba N, Viviani T, Fiad L

P129

You Don't Always Need a Transplant: Checkpoint Inhibitors Can Deliver Lasting Remissions in Relapsed and Refractory Classical Hodgkin Lymphoma

Radhakrishnan V, Shakeel R, Singh D, Lown R, Lim S, Dutton D, Pryce A, Bennett L, Bates A, Davies A, Johnson P

P130

Second-Generation Epigenetic Clocks Reveal Accelerated Biological Aging in Relapsed/Refractory Hodgkin Lymphoma

Shah M, Abhyankar A, Nassour N, Hernandez-Ilizaliturri F, Ohm J, Niu A

P131

Autologous Stem Cell Transplantation after Anti-PD-1 Therapy in Heavily Pretreated Patients with Relapsed/Refractory Classical Hodgkin Lymphoma: Real-World Outcomes

Protopopova I, Mochkin N, Sarzhevskiy V, Demina E, Melnichenko V, Shorokhov N, Samoylova A, Mamedova A, Bannikova A, Rukavitsyn A, Smirnova E, Bogatyrev V

P132

Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma in the Brentuximab Era: Updated Single-Center Experience

Milanovich N, Dziuba A, Marozava O, Strongin Y, Nechay O, Talako T, Volkovets N, Avadok A, Uss A

P133

Recurrent Hemophagocytic Lymphohistiocytosis and Hepatic Failure in EBV-Associated Hodgkin Lymphoma

Tobarra I, Bosch M, Fox M L, Castellvi J, García C, Abrisqueta P, Carpio C, Fuentes J K

P134

IMPACT OF PRE-TRANSPLANT BRENTUXIMAB VEDOTIN ON TOXICITIES AND OUTCOMES OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA

Sanchez C, Neto M, Osório F, Brito A I, Badior M, Carvalhais I, Carneiro A, Medeiros P, Molta F, Pinto A L, Pinto R, Trigo F

P135

Immunophenotyping of CD8+ T cells from classical Hodgkin Lymphoma patients treated with PD-1 blockade

Salaciak M, Al-Aubodah T, Worme S, Widawski L, Kleinman C L, Ragoussis I, Rys R, Abraham M, Rizzolo A, McCallum P, Goncalves C, Duns G, Steidl C, Del Rincon S, Mann K K, Piccirillo C, Mercier F E, Johnson N

P136

Post-ASCT Brentuximab Vedotin (BV) maintenance in high-risk relapsed/refractory Hodgkin lymphoma in the era of novel salvage therapies: a bias-adjusted analysis of 4 LYSA real-world cohorts.

Marouf A, Murari Mirimo T, Galtier J, Basile G, Dutari P, Rossi C, Cherblanc F, Chartier L, Bouabdallah K, Noel R, Ghesquières H, Deau-Fischer B

P137

Anti PD1 containing salvage regimen is highly effective in chemorefractory HL patients

Pierdomenico F, Freitas C, Viegas D, Coelho I, Barbosa M I, Ionita A, Carvalho S, Gomes Da Silva M

Resource Constrained Setting

Posters

P139


Implementation of BrECADD According to HD21 Standards in a Middle-Income Country: Barriers and Feasibility in Mexican Public Hospitals

Tecayehuatl Negrete L N, Rubalcava Lara L F, Santiago Jiménez G, Hernández Company A, Colunga Pedraza P R, Pineda Terreros B, Jacobo Pacheco M, Mejía Chávez M E, Arzate Ramírez K A, López Aparicio M C, Barreda González R A, Muñoz Gutierrez A X, Rangel Patiño J

SPEAKERS AND CHAIRS

Advani, Ranjana	Diepstra, Arjan	Linton, Kim
Aleman, Berthe	Dietrich, Caroline	Mascarin, Maurizio
Alig, Stefan	Eich, Hans Theodor	Mauz-Körholz, Christine
Ansell, Stephen	Eichenauer, Dennis	Mikhaeel, George
Aoki, Tomohiro	Evens, Andrew	Moskowitz, Alison
Armand, Philippe	Ferdinandus, Justin	Moskowitz, Craig H.
Aurer, Igor	Flertage, Jamie	Oertel, Michael
Baiocchi, Otavio	Fosså, Alexander	Oyiro Omondi, Peter
Baues, Christian	Friedberg, Jonathan	Pirosa, Maria
Behringer, Karolin	Geel, Jennifer	Plattel, Wouter
Binkley, Michael	Ghesquieres, Herve	Radford, John
Borchmann, Peter	Glimelius, Ingrid	Ricardi, Umberto
Borchmann, Sven	Heger, Jan-Michel	Robertz, Anne Sophie
Bröckelmann, Paul	Hentrich, Marcus	Salles, Gilles
Burton, Cathy	Herrera, Alex	Sengar, Manju
Büttner, Maximilian	Hertzberg, Mark	Shipp, Margaret
Castellino, Sharon	Hodgson, David	Specht, Lena
Chapuy, Björn	Hoppe, Richard	Steidl, Christian
Collins, Graham	Hutchings, Martin	Sureda, Anna
Cutter, David	Imber, Brandon	Tharmaseelan, Hishan
d'Amore, Francesco	Jauw, Yvonne	von Tresckow, Bastian
Dabaja, Bouthaina	Klapper, Wolfram	Yahalom, Joachim
Dann, Eldad J.	Küppers, Ralf	Zijlstra, Josée
Diefenbach, Catherine	Leppä, Sirpa	Zinzani, Pier Luigi
Diehl, Volker	Levis, Mario	

GÜRZENICH CONGRESS CENTER



First Floor

Großer Saal	Sat. 03.10.2026	Scientific Program, Scientific Symposia, Opening Ceremony
	Sun. / Mon. 04./05.10.2026	Scientific Program, Scientific Symposia
Isabellensaal	Sat. (noon) - Mon. 03.-05.10.2026	Exhibition Hall, Coffee Bar

Ground Floor

Foyer	Sat. - Mon. 03.-05.10.2026	Registration, Internet, Speakers Ready Room
Kleiner Saal and Foyer	Sat. 03.10.2026	Poster Presentation, Welcome Reception
Marsiliussaal	Sat. 03.10.2026	Workshop

Basement

Ratsstube	Sat. / Sun. 03./04.10.2026	Workshop
-----------	----------------------------	----------

WC: First Floor, Basement





ISHL14 APP

Scan QR-Code or visit app.ishl.eu
Further information is available at
www.hodgkinsymposium.org